Previous close | 0.4500 |
Open | 0.4734 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.4709 - 0.4835 |
52-week range | 0.3797 - 0.7200 |
Volume | |
Avg. volume | 4,764 |
Market cap | N/A |
Beta (5Y monthly) | -0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4040 |
Earnings date | 02 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ETOCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM ImmunoTech, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York, N.Y., on Wednesday, April 3, 2024, at 1:35 PM ET. In addition to the presentation, management will be available to participate in one-on-one me
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET. The call will be hosted by members of AIM’s leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Erasmus Medical Center Erasmus Medical Center OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”) studying the company’s drug Ampligen® (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma (“PDAC”). The manuscript